Gender Surgery Ban: Docs Say Wait Until 19

Scalpel,And,Rainbow,Lgbt,Ribbon,Pride,Symbol.,Sex,Change,Operation.

America’s largest plastic-surgery organization just broke with the medical establishment and told doctors to stop rushing irreversible “gender-affirming” surgeries on kids.

Story Snapshot

The American Society of Plastic Surgeons (ASPS) now recommends delaying gender-related surgeries until age 19, citing low-quality evidence and uncertain risk-benefit data.
ASPS emphasized its statement is professional guidance, not a binding clinical guideline, and it opposes criminalizing medical care.
The group’s move aligns with recent evidence reviews that also judged the research base to be weak, including the UK Cass Review and a U.S. HHS review.
Federal health leaders praised the shift as “sound science,” while major legacy medical groups continue to defend the interventions.

ASPS draws a bright line at age 19

The ASPS position statement released February 3, 2026 recommends postponing breast/chest, genital, and facial gender-related surgeries for patients under 19. ASPS, which represents more than 11,000 members and a large share of the specialty in the U.S. and Canada, said the evidence supporting these procedures for minors is low quality and does not provide solid risk-benefit answers. The statement also points to the irreversibility of surgery and unresolved questions about long-term harms.

ASPS also drew an ethical distinction that matters to families: uncertainty that may be tolerated in some pediatric plastic surgeries is not automatically acceptable here because these procedures can permanently alter sexual function, fertility options, and a child’s future development. The group framed its stance as forward-looking rather than punitive, noting an evolution in how the evidence has been evaluated over time and avoiding retroactive condemnation of clinicians who followed earlier norms.

What the society says it is—and is not—doing

ASPS stressed that its document is guidance, not a formal clinical guideline, meaning it does not carry the same step-by-step protocols or enforcement mechanisms as a specialty standard of care. The society also said it opposes criminalization of care, a point likely aimed at separating medical self-governance from the political push to prosecute physicians. For patients and parents, the practical takeaway is that ASPS is advising surgeons to proceed far more cautiously, especially where state law is changing.

That distinction matters because the current debate is not simply about whether adults can pursue medical procedures; it is about whether minors can consent to irreversible interventions amid weak evidence. ASPS’s recommendation to delay until 19 functionally moves these surgeries out of the pediatric category and closer to adulthood decision-making. For conservatives concerned about family rights and child protection, ASPS is signaling that “first, do no harm” requires higher evidentiary standards than activists and some institutions demanded in recent years.

Evidence reviews and the post-Biden political shift

ASPS’s reasoning tracks with a broader trend since 2024, when the UK Cass Review assessed the evidence base for pediatric gender medicine as low quality. A U.S. Department of Health and Human Services review in 2025 similarly found weak evidence for key interventions, reinforcing the argument that medicine moved faster than the data. ASPS began reviewing the evidence during the Biden era, and multiple reports now converge on the same problem: uncertain benefits, unclear long-term outcomes, and potentially permanent downsides.

Under the new administration’s health leadership, federal policy has also shifted toward restricting or conditioning funding tied to these services, and some hospitals have reportedly paused offerings under the pressure of funding and regulatory risk. HHS leaders publicly praised the ASPS position as grounded in “sound science” and framed it as opposition to “overmedicalization.” Major medical groups such as the American Academy of Pediatrics and the American Medical Association remain publicly supportive of “gender-affirming care,” creating an unusually visible fracture within institutional medicine.

Why this could reshape hospital policy and the broader debate

The near-term impact is straightforward: when the dominant professional society in plastic surgery recommends delay, risk managers and hospital boards take notice. Even without a binding rule, guidance like this can influence credentialing, informed-consent standards, and whether institutions feel comfortable offering surgeries to minors while evidence remains uncertain. ASPS also advised members to understand and comply with state laws, which are evolving rapidly and vary widely, adding another layer of caution for providers and parents.

American Society of Plastic Surgeons recommends against gender transition surgeries for minorshttps://t.co/HzEcScLKXx

— Matthew Yglesias (@mattyglesias) February 3, 2026

The longer-term question is whether other associations follow ASPS toward a more evidence-first posture or continue defending prior practices in the face of weak data. Based on ASPS’s statement and the cited evidence reviews, the core factual dispute is no longer easy to dismiss as partisan: the society is explicitly saying the quality of evidence is insufficient and the harms could be enduring. For readers who watched “woke” institutional pressure steamroll common sense in medicine, this development shows a measurable shift back toward restraint—at least in one major specialty.